RxDoctor Payments Data

Neil Dalal, DO

Hematology & Oncology · Downers Grove, ILNPI 1275775454

Payments from drug & device makers

$4,361in general payments, 2019–2025

Across 15 payments — averaging $290.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Athenex Pharmaceutical Division, LLC$350
  • Novocure GmbH$250
  • Merck$144
  • Johnson & Johnson$99
  • Seagen Inc.$85
  • plus $72 from 2 others

What the payments were for

  • Consulting fees$3,34077%
  • Speaking & faculty fees$60014%
  • Food & beverage$2375%
  • Education$1844%

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca3$3,361
Athenex Pharmaceutical Division, LLC2$350
Novocure GmbH1$250
Merck3$144
Johnson & Johnson1$99
Seagen Inc.1$85
Genentech USA, Inc.3$49
Novocure Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,361 in reported general payments places this provider in the 40th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$134,047
Medicare patients
328
Services billed
1,441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide16$395,601
ImbruvicaIbrutinib27$393,189
Lenalidomide17$272,266
XtandiEnzalutamide26$242,760
JakafiRuxolitinib Phosphate13$221,010
SprycelDasatinib12$163,970
BrukinsaZanubrutinib12$152,977
VenclextaVenetoclax30$132,985
EliquisApixaban118$117,025
XareltoRivaroxaban31$25,224
Erlotinib Hcl13$7,098
Anastrozole114$2,491
Hydroxyurea43$1,122
Tamoxifen Citrate35$1,088
Dexamethasone35$715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$99$25,22431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Downers Grove

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →